Waldenstroms macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14310%2F17%3A00111963" target="_blank" >RIV/00216224:14310/17:00111963 - isvavai.cz</a>
Alternative codes found
RIV/61988987:17110/17:A1801QUJ RIV/00843989:_____/17:E0106661 RIV/65269705:_____/17:00075968
Result on the web
<a href="https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.12959" target="_blank" >https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.12959</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/ejh.12959" target="_blank" >10.1111/ejh.12959</a>
Alternative languages
Result language
angličtina
Original language name
Waldenstroms macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection
Original language description
Waldenstroms macroglobulinemia (WM) is a complex disease characterized by apparent morphological heterogeneity within the malignant clonal cells representing a continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. At the molecular level, the neoplastic B cell-derived clone has undergone somatic hypermutation, but not isotype switching, and retains the capability of plasmacytic differentiation. Although by classical definition, WM is formed by monoclonal expansion, long-lived clonal B lymphocytes are of heterogeneous origin. Even more, according to current opinion, plasma cells also conform certain population with pathogenic and clinical significance. In this article, we review the recent advances in the WM clonal architecture, briefly describe B-cell development during which the molecular changes lead to the malignant transformation and mainly focus on differences between two principal B-lineage clones, including analysis of their genome and transcriptome profiles, as well as immunophenotype features. We assume that the correct identification of a number of specific immunophenotypic molecular and expression alterations leading to proper aberrant clone detection can help to guide patient monitoring throughout treatment and successfully implement therapy strategies directed against both B- and plasma cell tumor WM clones.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
European Journal of Haematology
ISSN
0902-4441
e-ISSN
1600-0609
Volume of the periodical
99
Issue of the periodical within the volume
6
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
469-478
UT code for WoS article
000416145400001
EID of the result in the Scopus database
2-s2.0-85031129649